ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Rating) CFO Mark C. Schneyer sold 15,310 shares of the business’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $22.50, for a total transaction of $344,475.00. Following the completion of the transaction, the chief financial officer now directly owns 21,905 shares in the company, valued at $492,862.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
ACADIA Pharmaceuticals Trading Up 4.8 %
ACADIA Pharmaceuticals stock opened at $24.31 on Friday. The stock has a market cap of $3.95 billion, a PE ratio of -26.71 and a beta of 0.54. The stock has a 50-day moving average price of $20.04 and a 200 day moving average price of $18.22. ACADIA Pharmaceuticals Inc. has a 52 week low of $12.24 and a 52 week high of $24.32.
ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Rating) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.06). The firm had revenue of $118.46 million for the quarter, compared to analysts’ expectations of $120.29 million. ACADIA Pharmaceuticals had a negative return on equity of 35.70% and a negative net margin of 28.05%. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.70) earnings per share. On average, equities analysts predict that ACADIA Pharmaceuticals Inc. will post -0.57 EPS for the current year.
Institutional Investors Weigh In On ACADIA Pharmaceuticals
Analyst Ratings Changes
A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group boosted their price target on shares of ACADIA Pharmaceuticals from $24.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, March 14th. Cantor Fitzgerald increased their target price on ACADIA Pharmaceuticals from $28.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 14th. JMP Securities lifted their price target on ACADIA Pharmaceuticals from $22.00 to $23.00 and gave the company an “outperform” rating in a research note on Tuesday, May 9th. Royal Bank of Canada reiterated an “outperform” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research report on Tuesday, March 14th. Finally, HC Wainwright boosted their target price on shares of ACADIA Pharmaceuticals from $25.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday, March 14th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $25.40.
ACADIA Pharmaceuticals Company Profile
ACADIA Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.
- Get a free copy of the StockNews.com research report on ACADIA Pharmaceuticals (ACAD)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.